BioSpace· Annalee Armstrong·· 4 hours agoPickScore71
Merck KGaA makes noise in hematology with $1.1B Silence buy
In brief
Merck KGaA will acquire UK siRNA company Silence Therapeutics for an enterprise value of approximately $1.1 billion and an equity value of approximately $1.3 billion. The offer of $20 per share represents an 82% premium to the 30-day average price. The deal is expected to close in the first quarter of 2027.
Why it matters
The brief gives the purchase price, enterprise and equity values, plus divesiran Phase 2 SANRECO response rate for comparison with other PV deals.
Source: BioSpace